Bristol Myers: positive Phase 3 data in NSCLC
(CercleFinance.com) - Bristol Myers Squibb reports positive data from the phase 3 CheckMate-816 study, which evaluated its Opdivo with chemotherapy as neoadjuvant treatment for adults with resectable non-small cell lung cancer (NSCLC).
According to the final analysis, the results showed a statistically and clinically significant improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.
These results are in addition to the previously reported primary endpoints of event-free survival and pathological complete response, which also achieved statistical significance. No new safety signals were observed.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
According to the final analysis, the results showed a statistically and clinically significant improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.
These results are in addition to the previously reported primary endpoints of event-free survival and pathological complete response, which also achieved statistical significance. No new safety signals were observed.
Copyright (c) 2025 CercleFinance.com. All rights reserved.